Advanced Lipid Management.
Personalized, physician-led advanced lipid management with direct access to your cardiology team. Proactive monitoring. Faster interventions. Better outcomes.
Understanding advanced lipid management.
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death globally, and low-density lipoprotein cholesterol (LDL-C) is its most established causal risk factor. The "lower is better" paradigm has been validated by decades of randomized controlled trial data — from the landmark 4S trial through IMPROVE-IT, FOURIER, and ODYSSEY Outcomes — demonstrating consistent, proportional reductions in cardiovascular events with LDL-C lowering. The 2018 ACC/AHA Cholesterol guidelines and 2019 ESC/EAS Dyslipidaemia guidelines now recommend LDL-C targets below 55 mg/dL for very high-risk patients. Yet achieving these targets remains challenging. Statin intolerance — whether true pharmacological intolerance or nocebo-driven — affects 5-30% of patients depending on the definition used. Many patients with familial hypercholesterolemia (FH), which affects 1 in 250 people, cannot reach target LDL-C on statin therapy alone. And emerging risk markers like lipoprotein(a), present at elevated levels in 20% of the population, identify residual risk that standard lipid panels miss entirely. Our concierge advanced lipid program goes beyond standard cholesterol management to provide comprehensive atherogenic particle assessment, PCSK9 inhibitor and bempedoic acid therapy when indicated, Lp(a) testing and risk stratification, and coronary artery calcium (CAC) scoring for personalized treatment intensity decisions.
Why concierge cardiology for this condition.
Advanced lipid management requires more than writing a statin prescription and checking a lipid panel once a year. True lipid optimization involves understanding advanced lipoprotein subfractions (ApoB, LDL particle number, Lp(a)), navigating complex medication regimens including injectable PCSK9 inhibitors, managing statin intolerance with systematic rechallenge protocols, and integrating imaging data like coronary artery calcium scores to personalize treatment intensity. In traditional practice, prior authorization for PCSK9 inhibitors alone can take weeks — time that leaves high-risk patients undertreated. Concierge cardiology provides dedicated prior authorization support and direct communication with insurers, same-day lipid panel review and medication adjustment, advanced testing that goes beyond standard panels, and coordination with genetics for familial hypercholesterolemia diagnosis and family cascade screening. The result is faster achievement of lipid targets and elimination of the treatment inertia that characterizes standard lipid care.
What we monitor.
Our management approach.
Expected outcomes.
Related concierge services.
Achieve optimal cholesterol levels with advanced lipid testing and personalized therapy from expert cardiologists.
Direct physician access, proactive monitoring, and personalized care plans. Concierge cardiology starting at $295/month.